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Abstract
Diastolic heart failure (HF) is also referred to as HF with preserved left ventricular systolic
function. The distinction between systolic and diastolic HFs is a pathophysiological one and
isolated forms of left ventricular dysfunction are rarely observed. In diastolic HF left ventricu-
lar systolic function is normal or only slightly impaired, and the typical manifestations of HF
result from increased filling pressure caused by impaired relaxation and compliance of the left
ventricle. The predisposing factors for diastolic dysfunction include elderly age, female sex,
obesity, coronary artery disease, hypertension and diabetes mellitus. Treatment of diastolic HF
is aimed to stop the progression of the disease, relieve its symptoms, eliminate exacerbations
and reduce the mortality. The management should include antihypertensive treatment, main-
tenance of the sinus rhythm, prevention of tachycardia, venous pressure reduction, prevention
of myocardial ischemia and prevention of diabetes mellitus. The European Society of Cardio-
logy specifies the type of therapy in diastolic HF based on: angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, beta-blockers, non-dihydropyridine calcium channel
blockers, diuretics. In order to improve the currently poor prognosis in this group of patients
the treatment of diastolic HF must be optimised. (Cardiol J 2010; 17, 6: 558–565)
Key words: diastolic heart failure, impaired relaxation, ejection fraction,
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Introduction
Diastolic heart failure (HF) is also referred to
heart failure with preserved ejection fraction (HF-
PEF). The distinction between systolic and diastolic
HFs is a pathophysiological one. Isolated forms of
left ventricular (LV) dysfunction are, however, rare-
ly observed. The majority of patients with HF have
both systolic and diastolic dysfunction [1, 2]. It is
estimated that in 55% of patients with systolic HF
diastolic dysfunction is also present [3].
Gaining an understanding of the pathomecha-
nisms underlying this disease entity is required to
make any attempts at its treatment. While the clini-
cal manifestations in systolic HF result from im-
paired contractility of the left ventricle coupled with
reduced ejection fraction (EF), LV systolic function
in HFPEF is normal or only slightly decreased (EF
≥ 40% in echocardiography). In this case the ma-
nifestations of HF result from increased filling pres-
sure caused by impaired relaxation and decreased
compliance of the left ventricle. Moreover, in the
pathomechanism of this form of HF, stiffness is not
only observed in LV myocardium but in the arter-
ies, which translates to high systemic resistance.
The differences between the two forms of HF
are also observed at the cellular level. Van Heer-
ebeek et al. [4] showed that the presence of elon-
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gated cardiac myocytes with a considerably elevat-
ed resting tone is typical of HFPEF. The stiffness
of the walls and decreased compliance of the myo-
cardium result from the increased amounts of col-
lagen in the interstitial layer. An abnormal expres-
sion of metalloproteinases and their inhibitors re-
sults in the predominance of degradation processes
over myocardial remodeling [4, 5].
Stroke volume not only depends on EF but also
on diastolic volume. In diastolic dysfunction the
impaired LV filling leads to the preservation of car-
diac output at the expense of elevated left atrial fill-
ing pressure. Hypertrophic cardiomyopathy is
a classic example of HF symptoms occurring with
a preserved very good systolic function. In extreme
cases patients manifest overt signs of HF at LVEF
values exceeding 70%.
The diagnosis of HFPEF is justified when the
patient complains about symptoms typical of HF,
the physical examination reveals venous congestion
and pulmonary congestion or even pulmonary ede-
ma, and an echocardiogram shows a normal or
slightly decreased LVEF. A Working Group of the
European Society of Cardiology (ESC) believes that
the diagnosis of diastolic HF requires three condi-
tions to be simultaneously satisfied [1]:
— presence of signs and/or symptoms of congesti-
ve HF (exercise intolerance is the first sign of
diastolic failure, as increased heart rate during
exercise shortens the duration of the already
impaired diastole impairing LV filling and secon-
darily leading to pressure overload of the pul-
monary circulation manifested by dyspnea); it
should, however, be borne in mind that identi-
fying the form of HF on the sole basis of the si-
gns is not possible, as the differential diagnosis
should include the following disease entities:
• cardiovascular conditions: ischemic heart
disease, valvular disease, hypertrophic and
restrictive cardiomyopathies, constrictive
pericarditis,
• non-cardiac conditions: lung diseases, obe-
sity, anemia, hyperventilation, hyperthyro-
idism, pulmonary hypertension;
— presence of normal or only mildly abnormal LV
systolic function — EF > 40–50%; EF is the
most important parameter for making the di-
stinction between systolic and diastolic HFs;
— documented impairment of relaxation, filling,
diastolic compliance or diastolic stiffness of the
left ventricle.
The above parameters are mainly assessed by
echocardiography. The echographic signs of dias-
tolic dysfunction are identified analysing abnorma-
lities of the diastolic phase from the mitral inflow
(in patients with sinus rhythm), the blood flow pro-
file in the pulmonary veins and the ratio of early
mitral filling flow velocity and early diastolic mitral
annular velocity (E/E’) measured by tissue Doppler
echocardiography [6].
The predisposing factors of diastolic dysfunc-
tion include elderly age, obesity and such co-mor-
bidities as hypertension and diabetes mellitus. The
risk of HFPEF is also increased in patients with
coronary artery disease of many years’ duration,
patients with a history of acute coronary syndromes
and patients with a history of myocarditis. A large
proportion of HFPEF patients are patients with LV
hypertrophy (LVH) of various aetiologies: in hyper-
trophic cardiomyopathy, aortic stenosis, chronic
kidney disease complicated by hypertension.
Population studies show that about 30–50% of
patients with congestive HF have normal LVEF val-
ues. Elderly patients (> 75 years of age), women,
hypertensive patients, often diabetics, and patients
with elevated body mass index (BMI) predominate
in this group [3].
The prognosis worsens with age. An analysis of
multiple studies suggests that over a period of five
years the percentage of HFPEF patients who die is
15% among those aged below 50, 33% among those
aged 50–70 and 50% among those aged over 70. Ac-
cording to Aurigemma [7], the survival of patients
with HFPEF is only slightly longer than that in pa-
tients with systolic dysfunction. Qwan et al. [3] point
out that the survival of patients with systolic HF is
systematically improving, while that of patients with
HFPEF does not change significantly. As HFPEF
may become the predominant form of HF in the near
future, every effort should be made to disseminate
the knowledge about its management. On the other
hand, it should be emphasised that it is incompara-
bly scantier than the knowledge about the manage-
ment of systolic HF. In contrast to systolic HF, to
which multiple randomised studies have been devot-
ed, treatment of HFPEF is nearly exclusively based
on recommendations of expert groups.
Treatment of HFPEF is aimed to stop the pro-
gression of the disease, relieve its symptoms, elimi-
nate exacerbations and reduce mortality. Success-
ful treatment of HF is conditional upon establish-
ing the etiology. Echocardiography is the principal
diagnostic tool. It is widely available, reproducible
and inexpensive, and its results are complemented
by the results of electrocardiography and chest
X-rays. The American College of Cardiology (ACC)
and the American Heart Association (AHA) guide-
lines emphasise that the measurement of brain
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natriuretic peptide (BNP) and N-terminal pro-B-
-type natriuretic peptide (NT-proBNP) is helpful in
risk stratification in patients with diastolic and sys-
tolic LV dysfunctions, although these should not be
used as markers of treatment efficacy (class IIa re-
commendations). This statement results from the
fact that the measurement of BNP for the purpos-
es of treatment monitoring has not been shown to
be associated with a reduction in mortality [8].
While such drugs as angiotensin converting
enzyme (ACE) inhibitors, angiotensin receptor
blockers (ARBs), beta-blockers, aldosterone anta-
gonists and diuretics are established treatments for
systolic HF, the use of these drugs in HFPEF is not
supported by multiple studies. According to the
AHA/ACC guidelines, the management of HFPEF
should involve [1, 8]:
— treatment of hypertension;
— maintenance of sinus rhythm;
— prevention of tachycardia;
— venous pressure reduction;
— prevention of myocardial ischemia.
Causative treatment, when used in the early
stages of the disease, preferably in stage A (high
risk of development of HF in the absence of symp-
toms) is most effective. Effective treatment of hy-
pertension, coronary artery disease and diabetes
mellitus reduces the risk of late complications.
Treatment of hypertension
Antihypertensive treatment is an important
element of management, as it is estimated that hy-
pertension coexists in about 60% of patients with
HFPEF. The close correlation between these two
disease entities supports intensive antihyperten-
sive treatment. It should, however, be borne in mind
that elderly patients predominate in this group and
it is necessary to avoid rapid blood pressure reduc-
tions. It is especially important because of the im-
paired function of the autonomic nervous system
and the risk of postural hypotension. Effective treat-
ment of hypertension results in immediate (im-
proved exercise capacity and alleviation of dyspnea)
and remote benefits. Normalization of systolic blood
pressure allows the left ventricle to work against
a lower afterload, which leads to a reduction in LV
diastolic volume and left atrial pressure. The indi-
rect beneficial effects of blood pressure normaliza-
tion are the improvement of oxygen balance in the
myocardium with the resulting improvement of
myocardial perfusion and a more rapid relaxation.
The remote benefits result from the suppression
or even reversal of LVH and from the decrease in
the percentage content of collagen in the wall of the
left ventricle.
Gandhi et al. [9] examined 38 patients with
acute pulmonary edema occurring in the course of
hypertension. The mean age of the patients was 67.
During the pulmonary edema the mean systolic
blood pressure was 200 ± 26 mm Hg, LVEF was
50 ± 15% and the wall motion score index (WMSI)
was 1.6 ± 0.6. The subsequent examinations 1–3
days after the resolution of acute LV failure showed
identical values of EF and WMSI with the only
change being a reduction in systolic blood pressure
(139 ± 17 mm Hg, p < 0.01). None of the patients
was diagnosed with mitral regurgitation during the
pulmonary edema episode.
The selection of the agent to be used in the
treatment of pulmonary edema in the course of
hypertension should principally be based on the
onset of action. The patient management should
include oxygen therapy, morphine, intravenous di-
uretics, and glyceryl trinitrate (GTN). It should,
however, be borne in mind that aggressive use of
diuretics and GTN in patients with WMSI may lead
to dangerous hypotension as a result of a rapid fall
in LV filling pressure and the resulting decrease in
cardiac output. The selection of the antihyperten-
sive agent for chronic use in patients with HFPEF
should take into consideration the role of angio-
tensin in the process of LVH and structural chang-
es in the LV wall associated with the increased col-
lagen content. Taking this aspect of management
into consideration, the drugs of choice should be
ACE inhibitors, AT1 receptor blockers and aldos-
terone antagonists. Already in 1993 Aronow and
Kronzon [10] showed that in elderly patients with
normal LVEF following myocardial infarction exer-
cise capacity is improved following the use of ena-
lapril. Several years later similar beneficial effects
of losartan were shown by Warner et al. [11]. They
also pointed out that limited exercise capacity is
a consequence of increased blood pressure, hence
the fundamental goal of treatment should be pre-
vention of blood pressure increase during exercise.
In the Losartan Intervention For Endpoint re-
duction in hypertension (LIFE) study [12], in the
group of patients with hypertension and LVH,
a higher efficacy of losartan vs atenolol was shown
in the reduction of the composite primary endpoint
(cardiovascular death, myocardial infarction or
stroke; p = 0.021) and in regression of LVH as-
sessed by echocardiography (p < 0.0001).
The Candesartan in Heart failure: Assessment
of Reduction in Mortality and morbidity-Preserved
(CHARM-Preserved) study [13] compared the
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effect of candesartan vs placebo in a group of NYHA
class II, III and IV patients with EF > 40%. Out of
the 3023 patients 1514 were randomized to cande-
sartan (target dose 32 mg/day) and 1509 to place-
bo. The primary endpoint was cardiovascular death
or hospitalization for HF. Over a period of 36.6
months the primary endpoint occurred in 333 (22%)
patients receiving candesartan and 366 (24%)
patients receiving placebo (p = 0.051). Cardiovas-
cular deaths occurred in both groups in 170 patients.
Hospitalizations for HF were less frequent in
the candesartan group vs placebo (230 vs 279,
p = 0.017) [13].
Another published study evaluating the effica-
cy of treatment with ACE inhibitors is the Perin-
dopril In Elderly People With Chronic Heart Fail-
ure (PEP-CHF) study [14]. A total of 850 patients
aged ≥ 70 with signs of HFPEF were randomized
to perindopril 4 mg or placebo. The primary com-
posite endpoint included all-cause mortality and un-
planned hospitalization for HF. The mean follow-
up period was 26.2 months. The primary endpoint
occurred in 107 placebo patients and 100 perindopril
patients (p = 0.545). The effect of perindopril treat-
ment was more beneficial in the first year of the
study. In this period the primary endpoint was ob-
served in 65 (15.3%) patients in the placebo group
and 46 (10.8%) patients in the perindopril group
(p = 0.055), and hospitalizations for HF were less
frequent in the perindopril group (p = 0.033). The
mortality rate in both groups was similar. A signif-
icant improvement in the NYHA class was observed
in patients receiving perindopril (p < 0.030). There
was also a significant improvement in the six-
minute walk distance in the perindopril group (p =
= 0.011). Perindopril treatment did not affect the
levels of NT-proBNP [14].
Based on the results of the above studies it may
be concluded that pharmacological intervention in
the renin–angiotensin–aldosterone system makes
it possible to improve exercise capability in HFPEF
patients and possibly reduces the risk of hospital-
ization for HF but does not affect the prognosis.
When discussing the results of the PEP-CHF study
we suggest that the severity of HF in the study pop-
ulation was mild, as evidenced by the NT-proBNP
levels (the mean values in the placebo and perin-
dopril groups were 453 pg/mL and 335 pg/mL, re-
spectively). Also the relative low number of adverse
events, much lower than expected, may support the
above hypothesis. Achieving a significant mortali-
ty risk reduction in such a population would there-
fore require a much longer follow-up and a consi-
derable increase in the sample size.
The investigators conducting the Valsartan In
Diastolic Dysfunction (VALIDD) study [15] of val-
sartan point to the fact that blood pressure reduc-
tion improves diastolic function of the myocardium
in hypertensive patients without HF and that this
effect is independent of the type of antihyperten-
sive agents used.
The ACA/AHA guidelines placed systolic and
diastolic blood pressure control in the highest class
of recommendations for the management of HFPEF
(class I of recommendations, level of evidence A) [8].
The effects of blood pressure normalization
include:
— reduction of LV end-diastolic pressure;
— reduction of left atrial pressure;
— improvement of relaxation leading to improved
early filling;
— decrease in myocardial ischemia (by reducing
oxygen demand and improving perfusion as
a result of reduced end-diastolic pressure);
— reduction of LVH and the resulting reduction
of the risk of development or progression of HF.
In the Systolic Hypertension in the Elderly
Program (SHEP) study [16] good control of isolat-
ed systolic hypertension allowed to significantly re-
duce the risk of HF and led to the reduction of LV
mass index by 13%. Treatment was based on chlo-
rthalidone and atenolol [16, 17].
Maintenance of sinus rhythm
and prevention of tachycardia
The ACC/AHA recommendations place ven-
tricular rate control in patients with atrial fibrilla-
tion (AF) and reversal to sinus rhythm in patients
with AF in class II recommendations with the level
of evidence A.
Under physiological conditions heart rate in-
crease improves relaxation and slightly reduces
diastolic pressure in the ventricle (Fig. 1). In dias-
tolic HF tachycardia results in delayed relaxation
and increased diastolic pressure.
In addition, the percentage contribution of the
diastole in relation to the systole decreases with
increasing heart rate. The diastole accounts for
nearly 70% of the cardiac cycle at a heart rate of
60 bpm, slightly over 50% at 120 bpm, and only 40%
at 180 bpm. The LV filling time is therefore con-
siderably shortened. Decreasing heart rate there-
fore results in reduced pressure in the early period
of the diastole by improving relaxation, and increas-
ing the ventricular filling time improves cardiac
output. The coronary perfusion time also increases,
which — together with the reduced oxygen con-
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sumption by the myocardium — improves myocar-
dial blood supply. The ESC experts recommend
beta-blockers or calcium channel blockers (CCB) for
decreasing heart rate [1].
The Swedish Doppler-echocardiographic
(SWEDIC) study [18] evaluated the effect of 6-
-month carvedilol treatment on the echocardiographic
parameters of diastolic function in 97 hypertensive
patients. There was a significant improvement vs
placebo in E/A from 0.72 to 0.83 (p = 0.046).
In one of our previous publications we showed
a beneficial effect of intravenous verapamil on the
LV filling parameters in patients with hypertrophic
cardiomyopathy [19].
Taking into account the close relationship be-
tween LV filling pressure and the patient’s exer-
cise capacity, reduction of heart rate in HFPEF
should be treated as a priority. In patients with
HFPEF, the heart is unable to take advantage of the
Frank-Sterling mechanism during exercise. A stiff
ventricle, despite elevated filling pressure, does not
increase in volume. As a consequence filling pres-
sure increases but cardiac output does not. This is
why, in great simplification, by reducing ventricu-
lar rate cardiac output can be improved. These
symptoms may be relieved by beta-blockers and
CCB. In the Study of Effects of Nebivolol Interven-
tion on Outcomes and Rehospitalization in Seniors
With Heart Failure (SENIORS) [20] nebivolol sig-
nificantly reduced mortality risk and cardiac hospi-
talization rate both in the group of patients with HF
and reduced EF and in the group of patients with
normal EF.
An important difference in the management of
both types of HF lies in the approach to using dihy-
dropyridine CCB, which may be beneficial in dias-
tolic dysfunction. This results, first of all, from their
documented relaxing effect on the myocardium. In
addition, their blood pressure and heart rate reduc-
ing properties are also taken advantage of.
The role of digitalis in the treatment of HF-
PEF is controversial, particularly in the case of
maintained sinus rhythm. In the Digitalis Inves-
tigation Group (DIG) [21] study 988 patients with
HF had EF > 45%, 492 of whom were randomized
to digoxin and 496 to placebo. The benefits of digi-
talis in this group were similar to those in the
group of patients with reduced EF. It is, however,
widely believed that the use of digitalis in HFPEF
should be limited to patients with AF, and the
principal goal of using this drug is ventricular rate
control. Digitalis should not be used if sinus
rhythm is maintained.
It should also be borne in mind that the im-
paired LV filling in diastolic dysfunction may be
further exacerbated by a non-sinus rhythm. For this
reason elimination of such arrhythmias as AF or
atrial flutter is an important element of treatment.
Where sinus rhythm cannot be maintained, a close
ventricular rate control is recommended. As a last
resort, atrioventricular node ablation with subse-
quent pacemaker implantation may be considered.
Figure 1. The relationship between relaxation rate and between left ventricular diastolic pressure and heart rate in
physiological conditions and in diastolic heart failure.
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Venous pressure reduction
An increase of wedge pulmonary artery pres-
sure of 1 mm Hg results in a 23% increase in all-
cause mortality risk and a 13% increase in the risk
of cardiovascular events. By reducing the wedge
pressure exercise capacity and the prognosis are
improved. The difficulty in optimizing LV filling
pressure in HFPEF lies in the fact that in this group
of patients the pressure/volume curve differs from
the physiological curve. In HFPEF patients even
a small decrease in filling pressure results in a very
marked reduction of LV diastolic volume, which
may lead to a significant reduction of cardiac out-
put. Increased filling pressure frequently fails to
significantly affect cardiac output but may put the
patient at risk of pulmonary edema.
Patients with HFPEF show a tendency towards
fluid retention, which is why restricted dietary in-
take of salt and fluids is recommended, while diure-
tics are the mainstay of symptomatic treatment. In
light of the above risks when using diuretics or long-
-acting nitrates considerable caution should exer-
cised and, particularly in the early phase of the treat-
ment, these drugs should be used under strict medi-
cal supervision. Diuretics do not directly affect the
myocardium, while nitrates improve the ability of
the left ventricle to increase its volume by releas-
ing nitrogen nitrate.
The effects of venous pressure reduction are
listed below:
— reduced LV compression Æ improved function;
— reduced LV end-diastolic pressure Æ improved
exercise capacity;
— improved oxygen balance in the myocardium
Æ elimination of ischemia.
The above therapy, however, requires consi-
derable caution due to the risk of excessive dehy-
dration leading to the manifestations of low-output
syndrome, poorly tolerated hypotension and im-
paired renal function. The doses of dehydrating
agents in this group of patients are much lower than
those in patients with systolic dysfunction.
Spironolactone is a drug that combines diure-
tic action with beneficial effects on the structure of
the left ventricle. The results of the ongoing Treat-
ment of Preserved Cardiac Function Heart failure
with an Aldosterone Antagonist (TOPCAT) and the
Aldosterone Receptor Blockade in Diastolic Heart
Failure (ALDO-DHF) study studies may provide
answers about the justifiability of treatment with an
aldosterone antagonist in HFPEF.
Prevention of ischemia
Myocardial ischemia is one of the most impor-
tant mechanisms underlying HFPEF. It is therefore
justified to use drugs that reduce oxygen consump-
tion by the myocardium (beta-blockers, CCB, ni-
trates) and revascularization to improve oxygen
supply to the myocardium. It should, however, be
noted that even successful revascularization does
not prevent recurrences of HF in patients with hy-
pertension and coronary artery disease [22].
Improved oxygen balance leads to:
— improved relaxation;
— reduced LV end-diastolic pressure;
— reduced risk of cardiac arrhythmias;
— reduced heart rate.
Zile [23] points out that in patients with dias-
tolic HF ischemia, especially subendocardial is-
chemia, is possible without significant atheroma-
tous changes in the epicardial arteries. It results,
among other things, from LVH, hypertension and
a high diastolic pressure which interferes with
perfusion.
Other treatments
Fukuda et al. [24] investigated the effect of st-
atins in patients with HFPEF managed with a beta-
blocker or a CCB, an ACE inhibitor or an ARB. Six-
ty-eight patients received a statin and the remain-
ing 69 did not. The authors showed that only the
use of a statin beneficially affected two-year survival
in this group of patients resulting in a 20% reduc-
tion in mortality in the group receiving statins (mor-
tality risk 0.06 vs 0.62, p = 0.005). There was also
a trend towards less frequent cardiovascular hos-
pitalizations (p = 0.082). The use of any of the oth-
er drugs resulted in no benefit. This is the first re-
port to demonstrate the efficacy of statins in HF-
-PEF, which most certainly requires further studies,
especially since statins are the first class of drugs
used in HFPEF that shows a documented benefi-
cial effect on survival. The beneficial effect of
statins in HFPEF may not only result from the stabi-
lization of atheromatous plaques in the coronary
arteries in patients in whom coronary artery disease
is the aetiological factor, but also from the docu-
mented effect of this drug class on the reduction of
LV mass and fibrosis. In a small study on rats Chang
et al. [25] showed a beneficial effect of rosuvasta-
tin on the LV myocardium in the form of suppressed
fibrosis with the resulting reduction in LV wall stiff-
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ness. These drugs also show a weak antihyperten-
sive action.
The management of HFPEF should not ignore
effective treatment of diabetes mellitus as a factor
exacerbating diastolic dysfunction. It is also justi-
fied to encourage obese patients to lose weight.
Summary
The ESC recommendations specify the type of
therapy in HFPEF. In order to reduce heart rate and
increase the diastole beta-blockers or non-dihydropy-
ridine CCB are recommended. In order to eliminate
fluid retention diuretics are used, administered with
considerable caution, while ACE inhibitors are used
to control blood pressure, suppress (regress) LVH and
to improve relaxation. High doses of ARB are recom-
mended to reduce the risk of hospitalization.
When the ACC/AHA 2009 guidelines were
being updated data from randomized clinical trials
did not contributed much to the current state of
knowledge about the pathomechanism and treat-
ment of diastolic dysfunction. It is still emphasised
that the key elements of management in this group
of patients include: very careful control of hydra-
tion, optimization of antihypertensive treatment
and, in the case of AF, restoration and maintenance
of sinus rhythm or ventricular rate control in pa-
tients with persistent arrhythmia. The physician
should also remember about revascularization in
symptomatic patients or, if it is suspected that dia-
stolic dysfunction could be caused by ischemia,
about taking steps to restore sinus rhythm in pa-
tients with AF.
In summary it should be emphasised that treat-
ment of HFPEF needs to be optimized in order to
improve the prognosis in this considerably numer-
ous group of patients. The commencement of treat-
ment is, however, conditional on the correct diag-
nosis based on a thorough history supplemented
with diagnostic investigations, mainly echocardio-
graphy. It seems, however, that optimal outcomes
can only be achieved if doctors are vigilant for this
particular form of HF with normal systolic function
of the left ventricle on the one hand, and rando-
mized studies are conducted which will allow to use
a therapy in line with evidence-based medicine.
This will result in improved long-term prognosis in
this group of patients, which continues to be poor
which — according to various researchers — is
associated with the annual mortality rate of 5–24%.
Taking into account the current state of know-
ledge, the management of HFPEF should be based on:
— causative treatment of: hypertension, type 2
diabetes mellitus, arrhythmias (prevention of
tachyarrhythmias and, if possible, maintenan-
ce of sinus rhythm), ischemic heart disease,
weight reduction, restricted salt intake;
— symptomatic treatment with: beta-blockers,
non-dihydropyridine CCB, ACE inhibitors,
ARB, diuretics, statins and aldosterone anta-
gonists.
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